Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy

BACKGROUND: The early diagnosis of hepatocellular carcinoma (HCC) can greatly improve patients’ 5-year survival rate, and the early efficacy assessment is important for oncologists to harness the anti-programmed cell death protein 1 (PD-1) immunotherapy in patients with advanced HCC. The lack of eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jiawei, Liu, Junwei, Tu, Xiaoxuan, Li, Bin, Tong, Zhou, Wang, Tian, Zheng, Yi, Shi, Hongyu, Zeng, Xun, Chen, Wei, Yin, Weiwei, Fang, Weijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804705/
https://www.ncbi.nlm.nih.gov/pubmed/35101942
http://dx.doi.org/10.1136/jitc-2021-003133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804705/
https://www.ncbi.nlm.nih.gov/pubmed/35101942
http://dx.doi.org/10.1136/jitc-2021-003133

Ejemplares similares